The analyst rating for GIANT BIOGENE (02367.HK) was adjusted to "Neutral" by UBS, with a target price slashed to $39.5, primarily due to a significant downward revision in the company's sales guidance and revenue forecasts. Morgan Stanley's report indicated that the company adjusted its 2025 sales growth expectation from 25% to flat or a mild decline, influenced by industry headwinds that hindered previously projected growth during key periods. Additionally, Morgan Stanley revised its revenue forecasts for 2025-27 down by 20%, 32%, and 35%, respectively, and anticipated a net profit drop of 8% year-over-year in 2025 and 2026, although a rebound of 20% was expected in 2027. The overall sentiment reflects concerns about the company's ability to achieve its growth targets amidst these challenges.
